Position in AMGN
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$33,079,662
-$931,214 QoQ
Shares Held
91,350
-5.5% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#278
of 3,140 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMGN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Mediolanum International Funds Ltd holds $526,708,653 across 9 Drug Manufacturers - General names. AMGN ranks #4 (6.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
202,670 | $243,088,498 | |
| 2 | JNJ |
Johnson & Johnson
|
397,098 | $100,850,979 | |
| 3 | MRK |
Merck & Co., Inc.
|
495,800 | $63,710,300 | |
| 4 | AMGN |
Amgen Inc
This page
|
91,350 | $33,079,662 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
545,919 | $31,455,852 | |
| 6 | ABBV |
AbbVie Inc.
|
117,411 | $29,545,304 | |
| 7 | PFE |
Pfizer Inc
|
720,894 | $17,359,127 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
50,027 | $6,320,411 |
All Filings in AMGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $33,079,662 | 91,350 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $34,010,876 | 96,663 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $29,323,048 | 89,588 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $16,608,316 | 58,853 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $4,016,156 | 14,384 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $6,638,818 | 21,309 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $6,395,844 | 24,539 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $7,265,835 | 22,550 | Shares | Sole | 2024-10-23 | |
| 2024-06-30 | $7,197,285 | 23,035 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $6,489,035 | 22,823 | Shares | Sole | 2024-05-03 | |
| No filing history on record for this holder in this stock. | ||||||